These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2571965)

  • 1. Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein.
    Weiner DB; Kokai Y; Wada T; Cohen JA; Williams WV; Greene MI
    Oncogene; 1989 Oct; 4(10):1175-83. PubMed ID: 2571965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation.
    Weiner DB; Liu J; Cohen JA; Williams WV; Greene MI
    Nature; 1989 May; 339(6221):230-1. PubMed ID: 2654648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the neu oncogene product in cell transformation and normal development.
    Kokai Y; Wada T; Myers JN; Brown VI; Dobashi K; Cohen J; Hamuro J; Weiner DB; Greene MI
    Princess Takamatsu Symp; 1988; 19():45-57. PubMed ID: 2908355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constitutively activated neu oncoprotein tyrosine kinase interferes with growth factor-induced signals for gene activation.
    Lehtola L; Sistonen L; Koskinen P; Lehväslaiho H; Di Renzo MF; Comoglio PM; Alitalo K
    J Cell Biochem; 1991 Jan; 45(1):69-81. PubMed ID: 1706346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential.
    Zhang HT; O'Rourke DM; Zhao H; Murali R; Mikami Y; Davis JG; Greene MI; Qian X
    Oncogene; 1998 Jun; 16(22):2835-42. PubMed ID: 9671404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of p185neu kinase activity and cellular transformation by co-expression of a truncated neu protein.
    Qian X; O'Rourke DM; Zhao H; Greene MI
    Oncogene; 1996 Nov; 13(10):2149-57. PubMed ID: 8950982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermolecular association and trans-phosphorylation of different neu-kinase forms permit SH2-dependent signaling and oncogenic transformation.
    Qian X; Dougall WC; Fei Z; Greene MI
    Oncogene; 1995 Jan; 10(1):211-9. PubMed ID: 7824275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene.
    Zhai YF; Beittenmiller H; Wang B; Gould MN; Oakley C; Esselman WJ; Welsch CW
    Cancer Res; 1993 May; 53(10 Suppl):2272-8. PubMed ID: 8097963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the neu proto-oncogene by Schwann cells during peripheral nerve development and Wallerian degeneration.
    Cohen JA; Yachnis AT; Arai M; Davis JG; Scherer SS
    J Neurosci Res; 1992 Apr; 31(4):622-34. PubMed ID: 1374476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu.
    Hong RL; Spohn WH; Hung MC
    Clin Cancer Res; 1999 Jul; 5(7):1884-91. PubMed ID: 10430096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract.
    Cohen JA; Weiner DB; More KF; Kokai Y; Williams WV; Maguire HC; LiVolsi VA; Greene MI
    Oncogene; 1989 Jan; 4(1):81-8. PubMed ID: 2563577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic activation of the PDGF beta receptor by the transmembrane domain of p185neu*.
    Petti LM; Irusta PM; DiMaio D
    Oncogene; 1998 Feb; 16(7):843-51. PubMed ID: 9484775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation.
    Burke CL; Lemmon MA; Coren BA; Engelman DM; Stern DF
    Oncogene; 1997 Feb; 14(6):687-96. PubMed ID: 9038376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 25 kDa polypeptide is the ligand for p185neu and is secreted by activated macrophages.
    Tarakhovsky A; Zaichuk T; Prassolov V; Butenko ZA
    Oncogene; 1991 Dec; 6(12):2187-96. PubMed ID: 1685016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations of critical amino acids affect the biological and biochemical properties of oncogenic A-Raf and Raf-1.
    Bosch E; Cherwinski H; Peterson D; McMahon M
    Oncogene; 1997 Aug; 15(9):1021-33. PubMed ID: 9285556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine phosphorylation of Shc proteins and formation of Shc/Grb2 complex correlate to the transformation of NIH3T3 cells mediated by the point-mutation activated neu.
    Xie Y; Li K; Hung MC
    Oncogene; 1995 Jun; 10(12):2409-13. PubMed ID: 7784091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine phosphorylation at the membrane-microfilament interface: a p185neu-associated signal transduction particle containing Src, Abl and phosphorylated p58, a membrane- and microfilament-associated retroviral gag-like protein.
    Juang SH; Carvajal ME; Whitney M; Liu Y; Carraway CA
    Oncogene; 1996 Mar; 12(5):1033-42. PubMed ID: 8649794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p185neu is phosphorylated on tyrosine in human primary breast tumors which overexpress neu/erbB-2.
    Wildenhain Y; Pawson T; Blackstein ME; Andrulis IL
    Oncogene; 1990 Jun; 5(6):879-83. PubMed ID: 1694290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo.
    Lofts FJ; Hurst HC; Sternberg MJ; Gullick WJ
    Oncogene; 1993 Oct; 8(10):2813-20. PubMed ID: 8104327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligand-independent oncogenic transformation by the EGF receptor requires kinase domain catalytic activity.
    Danielsen AJ; Maihle NJ
    Exp Cell Res; 2002 Apr; 275(1):9-16. PubMed ID: 11925101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.